Onkologie. 2021:15(3):145-146

Drug profile - emicizumab

Jiří Slíva
Ústav farmakologie 3. LF Univerzity Karlovy v Praze

Despite apparent advances in the treatment of hemophilia A, the disease is still treatable but not curable. Coagulation factor VIII substitution has its obvious limitations. This short article provides a brief overview of the pharmacological properties of emicizumab, a monoclonal antibody with potential for use in hemophilic patients without or with an inhibitor.

Keywords: hemophilia, coagulation, clotting factors, bleeding, emicizumab.

Published: May 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Drug profile - emicizumab. Onkologie. 2021;15(3):145-146.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017; 92(7): 695-705. Go to original source... Go to PubMed...
    2. Haya S. Prophylactic treatment in hemophilic patients with inhibitors. Blood Coagul Fibrinolysis. 2019; 30(1S Suppl. 1): S14-S18. Go to original source... Go to PubMed...
    3. SPC Hemlibra 30 mg/mL solution for injection. Source: https://www.ema.europa.eu. Accessed: 19 Feb. 2021.
    4. Nogami K. Bispecific antibody mimicking factor VIII. Thromb Res. 2016; 141(Suppl. 2): S34-35. Go to original source... Go to PubMed...
    5. Chavin SI. Factor VIII: structure and function in blood clotting. Am J Hematol. 1984; 16(3): 297-306. Go to original source... Go to PubMed...
    6. Shima M, Hanabusa H, Taki M, et al. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016; 374(21): 2044-2053. Go to original source... Go to PubMed...
    7. Yoneyama K, Schmitt C, Kotani N, et al. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clin Pharmacokinet. 2018; 57(9): 1123-1134. Go to original source... Go to PubMed...
    8. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11(1-2): 81-88. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.